SK Biopharmaceuticals Settles U.S. Patent Lawsuit Over Xcopri
SK Biopharmaceuticals has reached a settlement with Indian generic drug developer MSN Laboratories in a U.S. patent lawsuit regarding the epilepsy drug Xcopri. The agreement allows MSN to market a generic version between 2032 and 2039, ending litigation in Delaware federal court while leaving two separate lawsuits active. The dispute centers on the epilepsy drug … Read more